Suppr超能文献

过氧化物酶体增殖物激活受体γ激动剂:血压与水肿。

PPARgamma Agonists: Blood Pressure and Edema.

机构信息

Department of Biology, Indiana University-Purdue University Indianapolis, 723 West Michigan Street, SL 358 Indianapolis, IN 46202, USA.

出版信息

PPAR Res. 2010;2010:785369. doi: 10.1155/2010/785369. Epub 2009 Dec 22.

Abstract

Peroxisome proliferator activated receptor gamma (PPARgamma) agonists are widely used in the treatment of type 2 diabetes. Side effects of drug treatment include both fluid retention and a lowering of blood pressure. Data from animal and human studies suggest that these effects arise, at least in part, from drug-induced changes in the kidney. In order to capitalize on the positive aspect (lowering of blood pressure) and exclude the negative one (fluid retention), it is necessary to understand the mechanisms of action underlying each of the effects. When interpreted with known physiological principles, current hypotheses regarding potential mechanisms produce enigmas that are difficult to resolve. This paper is a summary of the current understanding of PPARgamma agonist effects on both blood pressure and fluid retention from a renal perspective and concludes with the newest studies that suggest alternative pathways within the kidney that could contribute to the observed drug-induced effects.

摘要

过氧化物酶体增殖物激活受体γ(PPARγ)激动剂被广泛用于治疗 2 型糖尿病。药物治疗的副作用包括体液潴留和血压降低。动物和人体研究的数据表明,这些作用至少部分是由药物引起的肾脏变化引起的。为了利用积极的方面(降低血压)并排除消极的方面(体液潴留),有必要了解每种作用的作用机制。当根据已知的生理原理进行解释时,目前关于潜在机制的假设产生了难以解决的谜团。本文从肾脏角度总结了目前对 PPARγ 激动剂对血压和体液潴留的影响的理解,并以最新的研究为结论,这些研究表明肾脏内的替代途径可能有助于观察到的药物诱导作用。

相似文献

引用本文的文献

6
Systematic drug repositioning based on clinical side-effects.基于临床副作用的系统药物再定位。
PLoS One. 2011;6(12):e28025. doi: 10.1371/journal.pone.0028025. Epub 2011 Dec 21.

本文引用的文献

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验